Newron Pharmaceuticals S.p.A.


8.1 (CHF) • At close July 24, 2024
Bedrijfsnaam Newron Pharmaceuticals S.p.A.
Symbool NWRN.SW
Munteenheid CHF
Prijs 8.1
Beurswaarde 154,284,750
Dividendpercentage 0%
52-weken bereik 4.09 - 11.2
Industrie Biotechnology
Sector Healthcare
CEO Mr. Stefan Weber

An error occurred while fetching data.

Over Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for

Vergelijkbare Aandelen

Santhera Pharmaceuticals Holding AG logo

Santhera Pharmaceuticals Holding AG


9.18 CHF

Kuros Biosciences AG logo

Kuros Biosciences AG


12.16 CHF

Evolva Holding SA logo

Evolva Holding SA


0.96 CHF

Molecular Partners AG logo

Molecular Partners AG


5.6 CHF

Relief Therapeutics Holding AG logo

Relief Therapeutics Holding AG


1.145 CHF

Financiële Gegevens

Cijfers zijn in miljoenen (CHF)

Cijfers zijn in miljoenen (CHF)